M3 Wealth Management LLC Purchases Shares of 23,777 Pfizer Inc. $PFE

M3 Wealth Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 23,777 shares of the biopharmaceutical company’s stock, valued at approximately $592,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PFE. Studio Investment Management LLC increased its stake in shares of Pfizer by 1.8% during the 4th quarter. Studio Investment Management LLC now owns 32,445 shares of the biopharmaceutical company’s stock worth $808,000 after purchasing an additional 581 shares during the last quarter. Integrity Alliance LLC. increased its stake in shares of Pfizer by 24.6% during the 4th quarter. Integrity Alliance LLC. now owns 113,598 shares of the biopharmaceutical company’s stock worth $2,829,000 after purchasing an additional 22,457 shares during the last quarter. Integrity Advisory Solutions LLC acquired a new position in shares of Pfizer during the 4th quarter worth about $217,000. Collaborative Wealth Managment Inc. acquired a new position in shares of Pfizer during the 4th quarter worth about $465,000. Finally, Smithfield Trust Co increased its stake in shares of Pfizer by 4.5% during the 4th quarter. Smithfield Trust Co now owns 68,677 shares of the biopharmaceutical company’s stock worth $1,709,000 after purchasing an additional 2,979 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PFE shares. UBS Group boosted their price objective on shares of Pfizer from $25.00 to $27.00 and gave the stock a “neutral” rating in a research note on Monday, April 13th. Wall Street Zen upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Saturday, May 9th. CICC Research started coverage on shares of Pfizer in a research note on Thursday, April 16th. They set an “outperform” rating and a $33.00 price objective on the stock. Morgan Stanley boosted their price objective on shares of Pfizer from $27.00 to $28.00 and gave the stock an “equal weight” rating in a research note on Friday, April 10th. Finally, Royal Bank Of Canada restated an “underperform” rating and set a $25.00 price objective on shares of Pfizer in a research note on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Pfizer currently has a consensus rating of “Hold” and an average target price of $28.61.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Several recent articles highlight bullish arguments for Pfizer, including analyst optimism around late-stage pipeline assets and the view that the stock could still have meaningful upside if upcoming drug trials and launches deliver. Article Title
• Positive Sentiment: Coverage also points to Pfizer’s attractive dividend yield and argues the payout remains supported, which may appeal to income-focused investors even while growth is uneven. Article Title
• Positive Sentiment: An article on Pfizer’s abrocitinib atopic dermatitis study nearing a data milestone suggests a near-term catalyst that could improve sentiment if results are favorable. Article Title
• Neutral Sentiment: One piece frames Pfizer as a “best medical stock” idea based on billionaire interest, but that is more of a screening-style thesis than a direct new company-specific catalyst. Article Title
• Neutral Sentiment: Another article says Pfizer’s investment narrative is shifting, with fair value estimates and analyst targets reflecting both pipeline hopes and revenue concerns, indicating a split Wall Street view rather than a clear breakthrough. Article Title
• Negative Sentiment: The biggest headwind is the Eliquis patent cliff, with projected multi-year revenue losses that could weigh on Pfizer’s future sales and earnings if new products do not offset the decline. Article Title

Pfizer Stock Down 0.2%

Shares of PFE opened at $25.86 on Wednesday. Pfizer Inc. has a 52 week low of $23.06 and a 52 week high of $28.75. The firm has a market cap of $147.39 billion, a P/E ratio of 19.74 and a beta of 0.35. The firm’s 50-day simple moving average is $26.82 and its 200 day simple moving average is $26.26. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.94 and a current ratio of 1.25.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 EPS for the quarter, beating analysts’ consensus estimates of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same quarter in the prior year, the business earned $0.92 EPS. Pfizer’s quarterly revenue was up 5.4% on a year-over-year basis. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, analysts forecast that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 8th will be paid a $0.43 dividend. The ex-dividend date is Friday, May 8th. This represents a $1.72 dividend on an annualized basis and a yield of 6.7%. Pfizer’s dividend payout ratio is 131.30%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.